Last reviewed · How we verify

Arpida AG — Portfolio Competitive Intelligence Brief

Arpida AG pipeline: 0 marketed, 0 filed, 3 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 3 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Intravenous linezolid Intravenous linezolid phase 3 Oxazolidinone antibiotic Bacterial 50S ribosomal subunit (23S rRNA) Infectious Disease
intravenous iclaprim or intravenous linezolid intravenous iclaprim or intravenous linezolid phase 3 Oxazolidinone antibiotic 50S ribosomal subunit Infectious disease
Intravenous iclaprim Intravenous iclaprim phase 3 Dihydrofolate reductase inhibitor Dihydrofolate reductase (DHFR) Infectious Disease

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Clinica Universidad de Navarra, Universidad de Navarra · 1 shared drug class
  2. Fundacion Clinic per a la Recerca Biomédica · 1 shared drug class
  3. Merck Sharp & Dohme LLC · 1 shared drug class
  4. Pfizer · 1 shared drug class
  5. Shenzhen Third People's Hospital · 1 shared drug class
  6. Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · 1 shared drug class
  7. University of Southern California · 1 shared drug class
  8. Wuhan Pulmonary Hospital · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Arpida AG:

Cite this brief

Drug Landscape (2026). Arpida AG — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/arpida-ag. Accessed 2026-05-13.

Related